Promotes tumor clearance by enhancing CD8+ T cell activation and antigen presentationInhaled agonists enhance efficacy of PD-1 blockade in lung tumors, remodeling the TME, enhancing CD8+ T cell infiltration, dendritic cell activation, and expansion of PD-1(low) T-bet(high) effector CD8+ T cellCo-administration with TLR3 agonists and anti-CTLA-4 or anti-LAG-3 enhanced vaccine-mediated tumor suppression. Here, CD8A is linked to neoplasm.